Health - 08:00
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
wire - news in brief
« BACK
Health - Pharmacology - 08:00
Health - Pharmacology - 14.06.2019
Pharmacology - Health - 14.06.2019
Health - Social Sciences - 13.06.2019
Pharmacology - Health - 12.06.2019
Pharmacology - Health - 12.06.2019
Pharmacology - Health - 11.06.2019
Health - Pharmacology - 10.06.2019
Pharmacology - Health - 06.06.2019
Life Sciences - Health - 06.06.2019 
How flow shapes bacterial biofilms
EPFL biophysicists have taken a systematic look into how bacterial biofilms are affected by fluid flow. The findings can give us clues about the physical rules guiding biofilm architecture, but also about the social dynamics that shape evolution. Although we tend to think of them as solitary sojourners of the world, bacteria are actually very social organisms.
Health - Pharmacology - 06.06.2019
Pharmacology - Health - 04.06.2019
Pharmacology - Health - 04.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 02.06.2019
Health - Pharmacology - 01.06.2019
Health - Business / Economics - 31.05.2019
Pharmacology - Health - 30.05.2019
Environment - Health - 30.05.2019 
European Scientists Call for Climate Action
A new report highlights an alarming range of health risks in Europe due to climate change and the benefits of a rapid phase out of fossil fuels. The report entitled "The imperative of climate action to protect human health in Europe" was published yesterday by the European Academies' Science Advisory Council (EASAC).
Health - Pharmacology - 29.05.2019
Health - Pharmacology - 24.05.2019
Health - Pharmacology - 24.05.2019
Pharmacology - Health - 24.05.2019
Health - Pharmacology - 24.05.2019
Pharmacology - Health - 23.05.2019
Pharmacology - Health - 22.05.2019
Health - Pharmacology - 21.05.2019
Health - Politics - 20.05.2019
Pharmacology - Health - 16.05.2019
Health - 16.05.2019 
Flu Prevention in Switzerland
A nationwide systematic survey of 97 organisations carried out by Swiss TPH shows that authorities, hospitals, institutions and organisations in Switzerland have long been committed to efforts against the flu.
Health - Pharmacology - 16.05.2019
Pharmacology - Health - 16.05.2019
Health - 15.05.2019
Health - Pharmacology - 14.05.2019
Health - 14.05.2019
Pharmacology - Health - 10.05.2019
Pharmacology - Health - 10.05.2019
Pharmacology - Health - 09.05.2019
Pharmacology - Health - 08.05.2019
Health - Pharmacology - 07.05.2019
Health - Life Sciences - 07.05.2019
Pharmacology - Health - 06.05.2019
Pharmacology - Health - 02.05.2019
Innovation / Technology - Health - 02.05.2019
Pharmacology - Health - 30.04.2019
Event - Health - 27.04.2019
Health - Business / Economics - 24.04.2019 
Two Decades of Swiss Leadership for New Malaria Medicines
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines.
Health - Pharmacology - 23.04.2019
Health
Results 1 - 50 of 1715.
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
EPFL biophysicists have taken a systematic look into how bacterial biofilms are affected by fluid flow. The findings can give us clues about the physical rules guiding biofilm architecture, but also about the social dynamics that shape evolution. Although we tend to think of them as solitary sojourners of the world, bacteria are actually very social organisms.
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar + Mekinist
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe
Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care
Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of
Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of
Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled
A new report highlights an alarming range of health risks in Europe due to climate change and the benefits of a rapid phase out of fossil fuels. The report entitled "The imperative of climate action to protect human health in Europe" was published yesterday by the European Academies' Science Advisory Council (EASAC).
FDA approves Novartis Piqray - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulve
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulve
AveXis Announces Innovative Zolgensma Gene Therapy Access Programs for US Payers and Families
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD 425,000
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD 425,000
AveXis receives FDA approval for Zolgensma , the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 , Zolg
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 , Zolg
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
Bern Center for Precision Medicine inaugurated
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
A nationwide systematic survey of 97 organisations carried out by Swiss TPH shows that authorities, hospitals, institutions and organisations in Switzerland have long been committed to efforts against the flu.
Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc
Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.
Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.
Novartis data at AAN show Gilenya is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Novartis data at AAN show Mayzent’s positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people with Type 2 or 3 spinal muscular atrophy No treatment-related safety findings leading to withdrawal seen to date in risdiplam trials Roche today announ
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people with Type 2 or 3 spinal muscular atrophy No treatment-related safety findings leading to withdrawal seen to date in risdiplam trials Roche today announ
FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
Novartis to highlight extensive long-term safety and efficacy data of Aimovig across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
Moving people and technology
On 2 and 3 May 2020 ' exactly one year from now ' the Swiss Arena will open its doors for the next edition of the Cybathlon.
On 2 and 3 May 2020 ' exactly one year from now ' the Swiss Arena will open its doors for the next edition of the Cybathlon.
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines.
Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.
Health - 08:00
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy